DDInter416 DDInter1959
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia.
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Olaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Sulfinpyrazone
Sulfinpyrazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Clofedanol
Clofedanol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Darifenacin
Darifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Fluconazole {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Clotrimazole {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Clotrimazole {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may lead to a major life threatening interaction when taken with {v} Cimetidine
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Clotrimazole (Compound) resembles Sulfinpyrazone (Compound) and Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Clotrimazole (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Clotrimazole (Compound) resembles Darifenacin (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Zanubrutinib
Clotrimazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Clotrimazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Zanubrutinib
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib